FCM
EVH icon

Farallon Capital Management’s Evolent Health EVH Stock Holding History

Farallon Capital Management’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,000
Closed -$31.9K – 119
2026
Q1 		$31.9K Hold
14,000
– – ﹤0.01% 170
2025
Q4 		$56K Hold
14,000
– – ﹤0.01% 149
2025
Q3 		$118K Hold
14,000
– – ﹤0.01% 134
2025
Q2 		$158K Hold
14,000
– – ﹤0.01% 126
2025
Q1 		$133K Hold
14,000
– – ﹤0.01% 130
2024
Q4 		$158K Sell
14,000
-625,000
-98% -$11M ﹤0.01% 134
2024
Q3 		$18.1M Buy
+639,000
New +$16.5M 0.08% 77
2024
Q2 		– Sell
-1,037,331
Closed -$34M – 175
2024
Q1 		$34M Sell
1,037,331
-1,126,578
-52% -$36M 0.14% 62
2023
Q4 		$71.5M Buy
2,163,909
+263,000
+14% +$7.44M 0.33% 53
2023
Q3 		$51.8M Hold
1,900,909
– – 0.24% 57
2023
Q2 		$57.6M Buy
1,900,909
+757,000
+66% +$24.5M 0.29% 65
2023
Q1 		$37.1M Buy
1,143,909
+841,909
+279% +$26.6M 0.2% 67
2022
Q4 		$8.48M Buy
+302,000
New +$8.66M 0.05% 114

Other funds holding EVH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Farallon Capital Management's EVH Position: Q2 2026 in Review

Farallon Capital Management sold out of Evolent Health (EVH) in Q2 2026, closing a stake of 14,000 shares — an estimated $31.9K sold.

Farallon Capital Management first reported a position in EVH in Q4 2022 and held it in 13 quarters. The position peaked at $71.5M in Q4 2023. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

  • Farallon Capital Management reported no remaining Evolent Health position as of Q2 2026 after selling out during the quarter.
  • Farallon Capital Management sold 14,000 Evolent Health shares in Q2 2026, an estimated $31.9K.
  • Farallon Capital Management first reported a position in Evolent Health in Q4 2022 and held it in 13 quarters.
  • Farallon Capital Management's Evolent Health position peaked at $71.5M in Q4 2023.
  • 199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.